William Bradley

Director William Bradley purchases 68,493 shares of GUTS at $0.73, +424.7% from prior holdings; stock down -76.2% from 52-week high, up +54.7% in 90 days.

Director William Bradley acquired 68,493 shares at $0.73 on 2026-06-10, quadrupling his non-derivative holdings to 84,622 shares. The buy occurred after a 90-day rally of +54.7%, positioning the stock at $0.72 against a 52-week high of $3.03. His prior trade at GUTS (March 2025) exhibited a 90-day return of +79.8%, aligning with his cross-ticker track record of 100% 90-day win rate, though the company faces fundamental headwinds: full-year net income was negative and annual revenue growth stands at -100.0% despite $9.2M in latest quarterly net income. The divergence between negative full-year fundamentals and positive near-term momentum, combined with the director's established pattern of well-timed purchases at this ticker, warrants investor scrutiny of whether this reflects confidence in a turnaround or is merely capitalizing on recent price recovery.

Director William Bradley buys 16,129 shares of GUTS at $1.26; 4 other insiders bought within 14 days amid -83.7% YTD decline and $-23.2M annual loss.

Bradley William, a director of Fractyl Health, purchased 16,129 shares at $1.26 on March 13, 2025, establishing a new position with zero prior holdings. This purchase occurred within a 14-day cluster of 4 additional insider buys at the same company, indicating synchronized accumulation at depressed valuations. The stock trades 83.7% below its 52-week high of $7.78 and 30-day volume reflects a 19.6% decline, while the company reported $-23.2M net income over its most recent full fiscal year despite $14.0K quarterly revenue. The coordinated buying activity by multiple insiders during a period of severe stock depreciation and sustained unprofitability warrants examination of whether this reflects confidence in unannounced developments or represents a broader pattern worth monitoring.